Adjunctive Aripiprazole in Treatment-Resistant Bipolar Depression

References

• Ketter TA (ed.) Advances in the Treatment of Bipolar Disorder. Washington, DC: American Psychiatric Publishing, Inc., 2005.
   Google Scholar
• Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, Leon AC, Rice JA, Keller MB: The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002; 59:530–537
   PubMed Web of Science ®Google Scholar
• Judd LL, Akiskal HS, Schettler PJ, Coryell W, Endicott J, Maser JD, Solomon DA, Leon AC, Keller MB: A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003; 60:261–269
   PubMed Web of Science ®Google Scholar
• Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW, Evans AR, Beymer K, Dube S, Tollefson GD, Breier A: Efficacy of olanzapine and olan-zapine-fluoxetine combination in the treatment of bipolar I depres-sion. Arch Gen Psychiatry 2003; 60:1079–1088
   PubMed Web of Science ®Google Scholar
• Goodwin FK, Murphy DL, Dunner DL, Bunney WE, Jr.: Lithium response in unipolar versus bipolar depression. Am J Psychiatry 1972; 129:44–47
   Google Scholar
• Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD: Lamictal 602 Study Group. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry 1999; 60:79–88
   Google Scholar
• Calabrese JR, Keck PE, Jr., Macfadden W, Minkwitz M, Ketter TA, Weisler RH, Cutler AJ, McCoy R, Wilson E, Mullen J: A random-ized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005; 162:1351–1360
   Google Scholar
• Gijsman HJ, Geddes JR, Rendell JM, Nolen WA, Goodwin GM: Antidepressants for bipolar depression: A systematic review of randomized, controlled trials. Am J Psychiatry 2004; 161:1537–1547
   PubMed Web of Science ®Google Scholar
• Manji HK, Zarate CA: Molecular and cellular mechanisms under-lying mood stabilization in bipolar disorder: Implications for the development of improved therapeutics. Mol Psychiatry 2002; 7(Suppl 1):S1–7
   Google Scholar
• Li X, Ketter TA, Frye MA: Synaptic, intracellular, and neuropro-tective mechanisms of anticonvulsants: Are they relevant for the treatment and course of bipolar disorders? J Affect Disord 2002; 69:1–14
   PubMed Web of Science ®Google Scholar
• Banki CM: Correlation between cerebrospinal fluid amine metab-olites and psychomotor activity in affective disorders. J Neuro-chem 1977; 28:255–257
   PubMed Web of Science ®Google Scholar
• Goodwin FK, Post RM, Dunner DL, Gordon EK: Cerebrospinal fluid amine metabolites in affective illness: The probenecid tech-nique. Am J Psychiatry 1973; 130:73–79
   PubMedGoogle Scholar
• Koslow SH, Maas JW, Bowden CL, Davis JM, Hanin I, Javaid J: CSF and urinary biogenic amines and metabolites in depression and mania. A controlled, univariate analysis. Arch Gen Psychiatry 1983; 40:999–1010
   PubMed Web of Science ®Google Scholar
• Tohen M, Sanger TM, McElroy SL, Tollefson GD, Chengappa KN, Daniel DG, Petty F, Centorrino F, Wang R, Grundy SL, Greaney MG, Jacobs TG, David SR, Toma V: Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry 1999; 156:702–709
   PubMed Web of Science ®Google Scholar
• Tohen M, Jacobs TG, Grundy SL, McElroy SL, Banov MC, Janicak PG, Sanger T, Risser R, Zhang F, Toma V, Francis J, Tollefson GD, Breier A: Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzapine HGGW Study Group. Arch Gen Psychiatry 2000; 57:841–849
   PubMed Web of Science ®Google Scholar
• Hirschfeld RM, Keck PE, Jr., Kramer M, Karcher K, Canuso C, Eerdekens M, Grossman F: Rapid antimanic effect of risperidone monotherapy: A 3-week multicenter, double-blind, placebo-con-trolled trial. Am J Psychiatry 2004; 161: 1057–1065
   Google Scholar
• Khanna S, Vieta E, Lyons B, Grossman F, Eerdekens M, Kramer M: Risperidone in the treatment of acute mania: double-blind, pla-cebo-controlled study. Br J Psychiatry 2005; 187:229–234
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Brecher M, Paulsson B, Huizar K, Mullen J: Quetiapine or haloperidol as monotherapy for bipolar mania-a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol 2005; 15:573–585
   PubMed Web of Science ®Google Scholar
• Bowden CL, Grunze H, Mullen J, Brecher M, Paulsson B, Jones M, Vagero M, Svensson K: A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry 2005; 66:111–121
   PubMed Web of Science ®Google Scholar
• Keck PE, Jr., Versiani M, Potkin S, West SA, Giller E, Ice K: Ziprasidone in the treatment of acute bipolar mania: A three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry 2003; 160:741–748
   PubMed Web of Science ®Google Scholar
• Potkin SG, Keck PE, Jr., Segal S, Ice K, English P: Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. J Clin Psychopharmacol 2005; 25: 301–310
   Google Scholar
• Keck PE, Jr., Marcus R, Tourkodimitris S, Ali M, Liebeskind A, Saha A, Ingenito G: A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipo-lar mania. Am J Psychiatry 2003; 160:1651–1658
   PubMed Web of Science ®Google Scholar
• Sachs G, Sanchez R, Marcus R, Stock E, McQuade R, Carson W, Abou-Gharbia N, Impellizzeri C, Kaplita S, Rollin L, Iwamoto T: Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol 2006; 20:536–546
   PubMed Web of Science ®Google Scholar
• Tohen M, Calabrese JR, Sachs GS, Banov MD, Detke HC, Risser R, Baker RW, Chou JC, Bowden CL: Randomized, placebo-con-trolled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 2006; 163:247–256
   PubMed Web of Science ®Google Scholar
• Keck PE, Jr., Calabrese JR, McQuade RD, Carson WH, Carlson BX, Rollin LM, Marcus RN, Sanchez R: A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 2006; 67:626–637
   PubMed Web of Science ®Google Scholar
• Inoue T, Domae M, Yamada K, Furukawa T: Effects of the novel antipsychotic agent 7-(444-(2,3-dichloropheny1)-1-piperazi-nyllbutyloxy)-3,4-dihydro -2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. J Pharma-col Exp Ther 1996; 277:137–143
   PubMed Web of Science ®Google Scholar
• Burris KB, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB: Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002; 302:381–389
   PubMed Web of Science ®Google Scholar
• Jordan S, Koprivica V. Chen R, Tottori K, Kikuchi T, Altar CA: The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 2002; 441:137–140
   PubMed Web of Science ®Google Scholar
• McQuade RD, Bums KB, Jordan S, K. T, Kurahashi N, Kikuchi T: Aripiprazole: a dopamine-serotonin system stabilizer. Int J Neu-ropsychopharmacol 2002; 5(Suppl 1):5176
   Google Scholar
• Barbee JG, Conrad EL Jamhour NJ: Aripiprazole augmentation in treatment-resistant depression. Ann Clin Psychiatry 2004; 16:189–194
   PubMedGoogle Scholar
• Sachs GS, Thase ME, Otto MW, Bauer M, Miklowitz D, Wisniewski SR, Lavori P. Lebowitz B, Rudorfer M, Frank E, Nierenberg AA, Fava M, Bowden C, Ketter T, Marangell L, Cala-brese J, Kupfer D, Rosenbaum IF: Rationale, design, and methods of the systematic treatment enhancement program for bipolar dis-order (STEP-BD). Biol Psychiatry 2003; 53:1028–1042
   Google Scholar